

1 **PFHpA alters lipid metabolism and increases the risk of metabolic dysfunction-associated**  
2 **steatotic liver disease in youth—a translational research framework**

3 **Authors:** Brittney O. Baumert<sup>\*1</sup>, Ana C. Maretta-Mira<sup>\*2</sup>, Zhenjiang Li<sup>1</sup>, Nikos Stratakis<sup>3</sup>, Yinqi  
4 Zhao<sup>1</sup>, Douglas I. Walker<sup>4</sup>, Hongxu Wang<sup>1</sup>, Fabian Christoph Fischer<sup>5</sup>, Qiran Jia<sup>1</sup>, Damaskini  
5 Valvi<sup>6</sup>, Scott M. Bartell<sup>7</sup>, Carmen Chen<sup>1</sup>, Thomas Inge<sup>8,9</sup>, Justin Ryder<sup>8,9</sup>, Todd Jenkins<sup>10</sup>,  
6 Stephanie Sisley<sup>11</sup>, Stavra Xanthakos<sup>10</sup>, Rohit Kohli<sup>12</sup>, Sarah Rock<sup>1</sup>, Sandrah P. Eckel<sup>1</sup>, Michele  
7 A. La Merrill<sup>13</sup>, Max M. Aung<sup>1</sup>, Matthew P. Salomon<sup>2</sup>, Rob McConnell<sup>1</sup>, Jesse Goodrich<sup>1</sup>, David  
8 V. Conti<sup>1</sup>, Lucy Golden-Mason<sup>2</sup>, Lida Chatzi<sup>1</sup>

9 **\*These authors contributed equally**

10 <sup>1</sup> *Department of Population and Public Health Sciences, Keck School of Medicine, University of*  
11 *Southern California, Los Angeles, CA, United States*

12 <sup>2</sup> *USC Research Center for Liver Diseases, Division of Gastrointestinal and Liver Diseases,*  
13 *Department of Medicine, Keck School of Medicine, University of Southern California, Los*  
14 *Angeles, CA, United States*

15 <sup>3</sup> *Barcelona Institute for Global Health, ISGlobal, Dr. Aiguader 88, 08003, Barcelona, Spain*

16 <sup>4</sup> *Gangarosa Department of Environmental Health, Rollins School of Public Health, 1518 Clifton*  
17 *Road, NE, Atlanta, GA, United States*

18 <sup>5</sup> *Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston,*  
19 *RI 02881, United States*

20 <sup>6</sup> *Department of Environmental Medicine and Climate Science, Icahn School of Medicine at*  
21 *Mount Sinai, New York, NY, United States*

22 <sup>7</sup> *Department of Environmental and Occupational Health, University of California, Irvine,*  
23 *Irvine, CA, United States*

24 <sup>8</sup> *Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL,*  
25 *United States*

26 <sup>9</sup> *Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States*

27 <sup>10</sup> *Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of*  
28 *Cincinnati College of Medicine, Cincinnati, OH, United States*

29 <sup>11</sup> *Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States*

30 <sup>12</sup> *Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, Los*  
31 *Angeles, CA, United States*

32 <sup>13</sup> *Department of Environmental Toxicology, University of California, Davis, CA, United States*

### 33 **Funding**

34 The results reported herein correspond to specific aims of grant R01ES030691 to Dr. Chatzi  
35 from the National Institute of Environmental Health Science (NIEHS). Additional funding from  
36 NIEHS supported Dr. Chatzi (R01ES029944, R01ES030364, U01HG013288, and  
37 P30ES007048, European Union: The Advancing Tools for Human Early Lifecourse Exposome  
38 Research and Translation (ATHLETE) project, grant agreement number 874583), Dr. Baumert  
39 (R01ES030691, R01ES030364, and T32-ES013678), Dr. Goodrich (P30ES007048 and  
40 U01HG013288), Dr. Aung (P30ES007048 and U01HG013288), Dr. Valvi (R01ES033688,  
41 R21ES035148 and P30ES023515), Dr. Walker (R01ES030691, U2CES030859, and  
42 R01ES032831), Dr. McConnell (P30ES007048, P2C ES033433), and Dr. La Merrill  
43 (R01ES030364), Dr. Conti (R21ES029681, R01ES030691, R01ES030364, R01ES029944,

44 P01CA196569, and P30ES007048), Dr. Sisley (R01DK128117–01A1). Dr. Stratakis received  
45 funding from European Union’s Horizon Europe research and innovation programme under the  
46 Marie Skłodowska-Curie Actions Postdoctoral Fellowships (101059245). Dr. La Merrill was  
47 additionally supported by the California Environmental Protection Agency (20-E0017). Dr.  
48 Sisley was additionally supported by Department of Agriculture (6250-51000-053). The Teen-  
49 LABS consortium is supported by cooperative agreements with the National Institute of Diabetes  
50 and Digestive and Kidney Diseases (NIDDK) through grants for a clinical coordinating center  
51 (UM1DK072493; Inge) and the Data Coordinating Center (UM1DK095710).

52

53 **Corresponding author:**

54 Lida Chatzi, PhD, Department of Population and Public Health Sciences, University of Southern  
55 California, Keck School of Medicine of USC, 2001 N. Soto Street, Los Angeles, CA 90032,  
56 USA. chatzi@usc.edu

57

58 **Conflict of interest disclosures.**

59 The authors declare that they have no conflicts of interest apart from Dr. Bartell who has  
60 provided paid expert assistance in legal cases involving PFAS exposed populations.

61 **Declaration of competing financial interests.**

62 All other authors declare they have no actual or potential competing financial interests.

63 **Human Subjects**

64 Ethics approval for this study was provided by the University of Southern California Institutional  
65 Review Board (IRB protocols HS-19-00057). Prior to participation, written informed  
66 assent/consent were obtained from participants and their guardians. The Teen–Longitudinal  
67 Assessment of Bariatric Surgery (Teen–LABS) study  
68 ([ClinicalTrials.gov](https://clinicaltrials.gov) number, [NCT00474318](https://clinicaltrials.gov/ct2/show/study/NCT00474318)) was designed as prospective, multicenter,  
69 observational study of consecutive cases of bariatric surgery offered to adolescents. The study  
70 methodology has been previously described.

## 71 **Acknowledgements**

72 The authors would like to acknowledge the significant contributions made by all Teen-LABS  
73 study personnel as well as study participants. Additionally, the authors would like to  
74 acknowledge the contributions made by Flemming Nielsen, PhD and Philippe Grandjean, MD,  
75 PhD—both lead the laboratory analysis of plasma-PFAS of Teen-LABS participants.

76

77 **Abstract**

78 To address the growing epidemic of liver disease, particularly in pediatric populations, it is  
79 crucial to identify modifiable risk factors for the development and progression of metabolic  
80 dysfunction-associated steatotic liver disease (MASLD). Per- and polyfluoroalkyl substances  
81 (PFAS) are persistent ubiquitous chemicals and have emerged as potential risk factors for liver  
82 damage. However, their impact on the etiology and severity of MASLD remains largely  
83 unexplored in humans. This study aims to bridge the gap between human and in vitro studies to  
84 understand how exposure to perfluoroheptanoic acid (PFHpA), one of the emerging PFAS  
85 replacements which accumulates in high concentrations in the liver, contributes to MASLD risk  
86 and progression. First, we showed that PFHpA plasma concentrations were significantly  
87 associated with increased risk of MASLD in obese adolescents. Further, we examined the impact  
88 of PFHpA on hepatic metabolism using 3D human liver spheroids and single-cell transcriptomics  
89 to identify major hepatic pathways affected by PFHpA. Next, we integrated the *in vivo* and *in*  
90 *vitro* multi-omics datasets with a novel statistical approach which identified signatures of  
91 proteins and metabolites associated with MASLD development triggered by PFHpA exposure. In  
92 addition to characterizing the contribution of PFHpA to MASLD progression, our study provides  
93 a novel strategy to identify individuals at high risk of PFHpA-induced MASLD and develop  
94 early intervention strategies. Notably, our analysis revealed that the proteomic signature  
95 exhibited a stronger correlation between both PFHpA exposure and MASLD risk compared to  
96 the metabolomic signature. While establishing a clear connection between PFHpA exposure and  
97 MASLD progression in humans, our study delved into the molecular mechanisms through which  
98 PFHpA disrupts liver metabolism. Our *in vitro* findings revealed that PFHpA primarily impacts  
99 lipid metabolism, leading to a notable increase of lipid accumulation in human hepatocytes after  
100 PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, regulation  
101 of lipid metabolism by PPAR- $\alpha$  showed a remarkable activation. Moreover, the translational  
102 research framework we developed by integrating human and in vitro data provided us  
103 biomarkers to identify individuals at a high risk of MASLD due to PFHpA exposure. Our  
104 framework can inform policies on PFAS-induced liver disease and identify potential targets for  
105 prevention and treatment strategies.

106

107

108

109

110

111

## 112 **Introduction**

113           Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as  
114 nonalcoholic liver disease (NAFLD)<sup>1</sup>, refers to a spectrum of liver disorders including the  
115 metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic  
116 steatohepatitis (NASH). A hallmark of MASLD is the fat accumulation (steatosis) in the liver  
117 due to chronic metabolic dysfunction<sup>2</sup>. MASLD management addresses long-term healthcare  
118 needs and generates substantial economic burden<sup>3</sup>. The prevalence of MASLD in children has  
119 been growing in recent years, paralleling the rise in childhood obesity and metabolic  
120 syndrome<sup>4,5</sup>. MASLD is now one of the most common chronic liver diseases in children  
121 worldwide, affecting approximately 10% of children in the general population<sup>5</sup>. Among children  
122 with overweight or obesity, the prevalence of MASLD is much higher, to an estimated of 30-  
123 40%<sup>4</sup>. Limited interventions are available for the improvement of MASLD in children<sup>6</sup>. Diet  
124 restrictions, physical activity interventions and FDA-approved drugs including GLP-1 receptor  
125 agonists<sup>7</sup> have been used with limited success in adolescents with MASLD<sup>8</sup>. This highlights the  
126 need for preventive measures, such as identifying and intervening on modifiable risk factors.

127           The traditional risk factors for MASLD, such as excess energy intake, sedentary lifestyle,  
128 and genetics, cannot fully explain the MASLD epidemic in children<sup>9</sup>. Moreover, emerging  
129 evidence indicates that exposure to endocrine-disrupting chemicals can promote metabolic  
130 changes that result in fatty liver disease - a hypothesis referred to as the ‘Toxicant Fatty Liver  
131 Disease’<sup>10-12</sup>. Per- and polyfluorinated substances (PFAS), a large class of synthetic fluorinated  
132 organic chemicals, are globally ubiquitous. These chemicals have been used in industrial  
133 applications and consumer products, including water-repellent textiles, nonstick coatings, and  
134 food packaging products, for over 60 years<sup>13</sup>. PFAS have been detected in blood of over 99% of

135 individuals in the US.<sup>14,15</sup> Production of certain PFAS, such as perfluorooctane sulfonate (PFOS)  
136 and perfluorooctanoate (PFOA), was voluntarily phased-out in the U.S. during the 2000s, yet  
137 their negative health effects remain a concern because of their long half-lives (1.8–6.2  
138 years).<sup>14,16-18</sup> Consequently, newer PFAS variants, known as replacements, have been introduced,  
139 featuring shorter biological half-lives, to mitigate environmental persistence.<sup>16</sup> However, many  
140 of these replacements lack regulation and thorough testing regarding potential health risks,  
141 particularly during crucial developmental stages.

142 Additional studies are needed to better understand the health effects of replacement  
143 PFAS. Research has established that PFAS can accumulate in the human body and preferentially  
144 accumulate in the liver<sup>19-21</sup>, where they can disturb several hepatic functions, especially lipid  
145 metabolism<sup>18,22-24</sup>. An abundance of evidence exists based on concordance between experimental  
146 and population findings that certain PFAS are hepatotoxic to humans and many studies point to  
147 PFAS-induced lipid disruption<sup>22</sup>. Nevertheless, several gaps persist in the literature, such as a)  
148 whether individuals classified as overweight/obese are more prone to PFAS-induced liver  
149 toxicity, b) whether understudied PFAS compounds including replacement PFAS can induce  
150 liver damage, and c) which metabolic pathways affected by PFAS are significant and indicative  
151 of liver damage<sup>18,22,24,25</sup>.

152 We propose a translational research framework to connect scientific findings from human  
153 and in vitro studies, aiming to understand how PFAS contribute to MASLD progression (see Fig.  
154 1). Our investigation focused on perfluoroheptanoic acid (PFHpA), a short-chain carboxylic  
155 PFAS compound found in high concentrations in the liver<sup>23</sup> which was strongly linked to  
156 MASLD risk and severity of disease in obese adolescents. Using an innovative approach, we  
157 assessed PFHpA's impact on liver metabolism in vitro by combining 3D human liver spheroids

158 with single-cell transcriptomics. This allowed us to identify the primary metabolic pathways  
159 affected by PFHpA. Subsequently, we integrated multi-omic datasets from the human and in  
160 vitro study using advanced statistical methods. Through this analysis, we identified protein and  
161 metabolite signatures associated with MASLD development due to PFHpA exposure. Our study  
162 presents a novel strategy to identify individuals at high risk of developing PFAS-induced  
163 MASLD and to develop early intervention strategies.

164



165 **Results**

166 **Human Study: PFHpA increases the risk for MASLD in adolescents – Insights into**  
167 **Steatosis Severity and Disease Progression**

168 The current project included 136 adolescents with severe obesity who underwent bariatric  
169 surgery. Based on liver biopsies fifty-five (40%) participants were categorized as non-MASLD,  
170 51 (38%) as MASLD not MASH, and 30 (22%) as MASH. Among 8 PFAS congeners, plasma-  
171 PFHpA (mean = 0.13 ng/mL, SD = 0.12 ng/mL) was the sole PFAS congener significantly  
172 associated with both MASLD and MASH (Fig. S1, Table S1). Among adolescents in the Teen-  
173 LABS study, we observed 68% higher odds of MASLD per doubling of PFHpA (OR: 1.68, 95%  
174 CI: 1.19, 2.37) (Fig. S1, Table S1). We observed a significant dose-dependent relationship with  
175 PFHpA ( $p$  for trend=0.002), indicating a biological gradient in MASLD risk across exposure  
176 octiles (Fig. 2b). Furthermore, PFHpA exhibited significant associations with several indicators  
177 of disease severity, including the degree of steatosis (OR=1.61, 95% CI: 1.16, 2.24 for mild  
178 steatosis and OR=1.88, 95% CI: 1.22, 2.89 for moderate steatosis), fibrosis (OR =1.49, 95% CI:  
179 1.04, 2.14), and MASLD activity score (MAS) (OR=3.04, 95% CI: 1.78, 5.21). (Fig. 2c).

180

181 **Human Study: PFHpA Affects Lipid Metabolism, Oxidative Stress, and Inflammation in**  
182 **Adolescents**

183 Using Metabolome-Wide Association Study (MWAS) and Proteome-Wide Association Study  
184 (PWAS) approaches, we identified significant alterations in 51 metabolites and 55 proteins  
185 significantly altered by PFHpA exposure (Fig. 3a & 3b). Ingenuity Pathway Analysis (IPA)  
186 revealed the biological pathways affected by PFHpA (Fig. 3c & 3d). Specifically, pathways

187 related to inflammation were enriched, including the Inflammation pathway influenced by  
188 altered metabolites, and the Inflammatory Response and Cell Movement of Dendritic Cells  
189 pathways affected by altered proteins. We also observed an increase in the Synthesis of Reactive  
190 Oxygen Species pathway by metabolites, underscoring the role of inflammation and oxidative  
191 stress in PFHpA toxicity. Additionally, disruptions in lipid metabolism were evident, with  
192 enrichment of pathways such as Synthesis of Lipid and Concentration of Lipid, indicating lipid  
193 dysregulation as a potential consequence of PFHpA exposure. PWAS IPA analysis further  
194 emphasized PFHpA's associations with immune response, showing enrichment in immunity-  
195 related pathways by PFHpA-associated proteins. These pathways include Recruitment of  
196 Mononuclear Leukocytes, Formation of Lymphoid Tissue, Cell Proliferation of T Lymphocytes,  
197 and Cell Death of Lymphatic System Cells.

198

### 199 ***In vitro* study: PFHpA disturbs lipid metabolism in human liver spheroids.**

200 To determine the involvement of PFHpA in MASLD progression, we performed an *in vitro*  
201 assay to expose human liver spheroids comprised of human primary hepatocytes and non-  
202 parenchymal cells to PFHpA for 7 days in low-glucose media (Fig. 1b). Subsequent analysis  
203 through single-cell RNA sequencing (scRNA-seq) revealed the transcriptomic alterations in the  
204 cells composing the liver spheroids. Of note, we identified hepatocytes, T cells, Kupffer cells and  
205 NK cells (Fig. 4a). B cells were detected in a very reduced number and therefore were not  
206 included in the further analysis. Overall, we found that PFHpA exposure altered the expression  
207 of 472 genes in liver spheroids, with 156 genes upregulated and 316 genes downregulated.  
208 Analyzing the hepatic cell populations, we observed that hepatocytes and T cells exhibited the  
209 most pronounced numbers of differentially expressed genes (DEGs), with 263 (137 up and 126

210 down) and 383 (98 up and 285 down) DEGs respectively (Fig. 4b). NK cells showed 26 DEGs  
211 (19 up and 7 down) and Kupffer cells only showed the upregulation of 1 gene. Pathway analysis  
212 using IPA highlighted a notable impact of PFHpA on liver metabolism. In the whole liver  
213 spheroids, as well as the hepatocytes and T cells, we observed a substantial upregulation of  
214 pathways involved in lipid metabolism (48%, 45%, and 40% respectively), amino acid  
215 metabolism (21%, 18%, and 20% respectively), and detoxification pathways (14%, 14%, and  
216 10% respectively) indicating a significant disturbance induced by PFHpA exposure (Fig. 4c-e).  
217 Furthermore, PFHpA exposure led to the upregulation of peroxisome proliferator-activated  
218 receptor alpha (PPAR- $\alpha$ ) activation and fatty acid oxidation in human hepatocytes (Fig. 4f). Most  
219 pathways involved in hepatocyte lipid metabolism were related to lipid anabolism (lipogenesis),  
220 with the upregulation of several lipid biosynthesis, including cholesterol. This observation was  
221 confirmed by Nile Red imaging of spheroid lipid accumulation (Fig. 4g), which showed that  
222 liver spheroids exposed to PFHpA significantly accumulate more lipids than control spheroids  
223 ( $p=0.01$ ) (Fig. 4h). Although PFHpA exposure also activates lipid metabolism in T cells, the  
224 upregulated pathways were primarily related to nuclear hormone receptors activation, without a  
225 direct impact on lipid biosynthesis as observed in hepatocytes (Fig. S2). These findings  
226 underscore the pivotal role of PFHpA in disrupting lipid metabolism, particularly in hepatocytes,  
227 shedding light on the potential PFHpA contribution to MASLD pathogenesis.

## 228 **Unveiling Biomarker Signatures for PFHpA-induced MASLD through Multi-omics** 229 **Integration**

230 We integrated data from the human and the in vitro studies to identify plasma biomarkers  
231 indicative of PFHpA-induced MASLD using the OmicsNet 2.0 platform. Specifically, our  
232 analysis combined 156 upregulated genes (GEX) from the in vitro study with 42 metabolites

233 (MWAS) and 28 proteins (PWAS) upregulated in the human study (Fig. 1c). OmicsNet 2.0  
234 identified pathways showing significant overlap between GEX-MWAS and GEX-PWAS  
235 datasets. We identified a metabolomic signature of PFHpA-induced MASLD consisting of 19  
236 metabolites involved in lipid metabolism, amino acid metabolism, nutrient uptake, energy  
237 metabolism, and vitamin and nucleic acid metabolism (Fig. 5b). Additionally, a proteomic  
238 signature was defined, comprising 6 proteins from pathways involved in lipid degradation,  
239 vitamin metabolism, immune response, detoxification, and cancer (Fig. 5c).

240 Next, we integrated these overlapping features in a latent unknown clustering with integrated  
241 data (LUCID) model to assess the association between PFHpA exposure, multi-omics signatures,  
242 and MASLD risk.<sup>26</sup> This approach categorized individuals into groups based on similarities  
243 across PFHpA exposure, proteome, metabolome signatures, and disease outcomes, focusing on  
244 disease risk rather than stratification.

245 Figure 6 illustrates the joint associations between PFHpA and two latent clusters (profiles) of  
246 each omic layer (metabolome and proteome), identifying low and high MASLD risk clusters  
247 using unsupervised LUCID and logistic regression models. PFHpA showed a stronger  
248 association with the high-MASLD risk cluster characterized by proteins (OR = 2.73) compared  
249 to its association with the low-risk cluster characterized by metabolites (OR = 1.05). Notably,  
250 individuals in proteome profile 1 had significantly higher odds of MASLD (OR = 7.08) than  
251 those in proteome profile 0, while individuals in metabolome profile 1 had lower odds of  
252 MASLD (OR = 0.51) compared to those in metabolome profile 0. This designates metabolome  
253 profile 0 and proteome profile 1 as high-risk multi-omic profiles.

254 Fig. 6b describes the high and low risk for MASLD groups of individuals by the clusters of  
255 metabolites and proteins that differentiate these risk groups. Notably, tryptophan,

256 glycochenodeoxycholic acid, and deoxycarnitine emerged as predominant metabolome features  
257 distinguishing high and low-risk profiles. Negative scaled values of metabolome features, with  
258 the exception of Trans-4-Hydroxy-L-Proline and 5-Aminovaleric acid, tended to correlate with a  
259 higher risk of MASLD. Conversely, positive scaled values of proteome features defined a higher  
260 risk of MASLD. Remarkably, HYAL1, F7, CA5A, C2, ADH4, and ACY1 exhibited similar  
261 scaled values ranging from 0.21 to 0.25 among high-risk profiles, while ranging from -0.63 to -  
262 0.52 among low-risk profiles.

## 263 **Discussion**

264 We demonstrated a significant link between exposure to PFHpA and the MASLD risk  
265 and severity of disease, and further elucidated the molecular and cellular mechanisms underlying  
266 this association. The Teen-LABS study is a highly unique resource—providing the opportunity  
267 to investigate the relationship between PFAS and MALD using a cohort with largely extreme  
268 obesity and consistent availability of well characterized liver biopsies for the diagnosis of  
269 MASLD<sup>27</sup>. Like other PFAS compounds, PFHpA is persistent in the environment and has been  
270 detected in water, air, soil, and biota worldwide. The half-life of PFHpA in humans is  
271 approximately 2 months<sup>28</sup>. PFHpA can be formed as a minor degradation product of long-chain  
272 PFAS<sup>29-31</sup>. Although PFHpA has gained attention in recent years, the relatively few studies  
273 investigating it may reflect a combination of factors including historical research priorities,  
274 technical challenges, and resource limitations. While previous research has established a  
275 connection between PFHpA exposure, along with other short and long-chain PFAS, and severity  
276 of liver steatosis and fibrosis in MASLD among adults<sup>32</sup>, our study marks the first time that  
277 exposure to PFHpA has been associated with MASLD in adolescents. Beyond the association  
278 with histological markers of MASLD, our findings indicate that adolescents with obesity

279 exposed to PFHpA also exhibit alterations in plasma levels of proteins and metabolites that  
280 signal inflammation and dysfunction in lipid metabolism.

281 To delve deeper into the molecular mechanisms underlying PFHpA-associated MASLD,  
282 we conducted *in vitro* experiments to examine how PFHpA affects liver metabolism using the  
283 3D human liver spheroid co-culture model. Our study used single-cell transcriptomics to  
284 evaluate PFHpA impact on each hepatic cell population from the liver spheroids. Our findings  
285 revealed that PFHpA primarily impacts lipid metabolism, leading to a notable increase in  
286 anabolic events in human primary hepatocytes, with significant hepatic lipid accumulation after  
287 PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, the  
288 ‘Regulation of lipid metabolism by PPAR- $\alpha$ ’ and ‘Fatty Acid  $\beta$ -oxidation I’ pathways showed  
289 the strongest activation. This suggests that PFHpA promotes hepatocyte lipogenesis likely  
290 through peroxisome proliferator-activated receptor (PPAR)- $\alpha$  signaling. PPARs are members of  
291 the nuclear hormone receptor superfamily, acting as ligand-activated transcription factors<sup>33</sup>. In  
292 the liver, PPAR- $\alpha$  plays a crucial role in regulating fatty acid oxidation, and lipid and lipoprotein  
293 metabolism<sup>34</sup>, and previous research has shown that various PFAS, including PFHpA, can  
294 activate PPAR- $\alpha$  in cell lines and animal models<sup>35-37</sup>. Recently, Yang et al proposed that hepatic  
295 lipid metabolism disruption caused by PFOA and PFOS depends on the PPAR- $\alpha$ /ACOX1 axis<sup>38</sup>.  
296 Our *in vitro* analysis indicates this pathway is disrupted in hepatocytes but not immune cells. We  
297 found that ACOX1 expression was upregulated and integrated the pathway ‘Regulation of lipid  
298 metabolism by PPAR- $\alpha$ ’ in hepatocytes from spheroids exposed to PFHpA. In contrast, while  
299 PPAR- $\alpha$  signaling was also upregulated in T cells exposed to PFHpA, ACOX1 was not  
300 differentially expressed and no lipid biosynthesis pathways were detected (Excel Supplement B).

301 Our findings indicate that PFHpA alter signaling of PPAR- $\alpha$ /ACOX1 axis in hepatocytes but not  
302 T cells, to instigate abnormal hepatic lipid metabolism in humans.

303 Leveraging a novel statistical approach, we integrated *in vivo* and *in vitro* datasets to identify the  
304 proteomic and metabolomic signatures that could be used as potential indicators of PFHpA-  
305 induced MASLD. LUCID analysis was then applied to investigate whether these PFHpA-derived  
306 OMICs biomarkers correlated with disease outcome. Notably, our analysis revealed that the  
307 proteomic signature exhibited a stronger correlation between PFHpA exposure and MASLD risk  
308 compared to the metabolomic signature.

309 In addition to establishing a clear connection between PFHpA exposure and MASLD disease in  
310 humans, our study elucidated the intricate molecular mechanisms by which PFHpA impacts liver  
311 metabolism. Moreover, we developed a translational research framework that allows us to  
312 identify individuals at high risk of MASLD due to PFHpA exposure. Our framework not only  
313 advances the current knowledge on PFAS impact on chronic liver diseases but also provides  
314 critical information for future policies aiming at mitigating the detrimental impact of PFAS on  
315 human health. Finally, our findings offer potential new targets for MASLD treatment strategies  
316 by determining specific molecular targets implicated in PFAS-induced liver disease.

317

318

319

320 **Methods**

321

322 **Study population.** The study is based on data from the Teen-LABS study (ClinicalTrials.gov  
323 number, NCT00465829), a prospective, multicenter, observational study of adolescents ( $\leq 19$   
324 years of age) who underwent bariatric surgery from 2007 through 2012. The participants were  
325 enrolled at five clinical centers in the United States: Cincinnati Children’s Hospital Medical  
326 Center (Cincinnati, Ohio), Nationwide Children’s Hospital (Columbus, Ohio), the University of  
327 Pittsburgh Medical Center (Pittsburgh, Ohio), Texas Children’s Hospital (Houston, Texas) and  
328 the Children’s Hospital of Alabama (Birmingham, Alabama)<sup>27</sup>. Study inclusion criteria included  
329 (1) adolescents up to age 19, (2) adolescents approved for bariatric surgery, (3) agreement to  
330 participate in the Teen-LABS study, demonstrated through the signing of Informed  
331 Consent/Assent<sup>27</sup>. The Teen-LABS steering committee, which included a site principal  
332 investigator from each participating center, worked in collaboration with the data coordinating  
333 center and project scientists from the National Institute of Diabetes and Kidney Disease (NIH-  
334 NIDDK) to design and implement the study<sup>27</sup>. All bariatric procedures were performed by  
335 surgeons who were specifically trained for study data collection (Teen-LABS–certified  
336 surgeons)<sup>27,39-41</sup>. The present study includes 136 participants with plasma collected at the time of  
337 surgery. The study protocol, assent/consent forms, and data and safety monitoring plans were  
338 approved by the Institutional Review Boards of each institution and by the independent data and  
339 safety monitoring board prior to study initiation<sup>27</sup>. Written informed consent or assent, as  
340 appropriate for age, was obtained from all parents/guardians and adolescents<sup>27</sup>. Additionally, the  
341 study was approved by the University of Southern California review board.

342



343 **Data collection.** Standardized methods for data collection have been described previously<sup>27,39-41</sup>.  
344 Fasting blood specimens were drawn at the preoperative visit. Liver histology and liver biopsy  
345 methodology has been previously detailed<sup>41</sup>, however, briefly, liver biopsies were obtained by  
346 core needle technique after induction of anesthesia and before performing the bariatric surgery  
347 procedure. Due to the observational study design and lack of published consensus on whether  
348 intra-operative liver biopsies should be standard of care at time of bariatric surgery, the decision  
349 to perform a liver biopsy was deferred to the surgical teams at each site. Accordingly, 99% of all  
350 biopsies were performed at the sites where intraoperative biopsy was standard of care. Liver  
351 biopsy specimens were stained with hematoxylin-eosin and Masson's trichrome stains and  
352 reviewed and scored centrally by an experienced hepatopathologist using the validated MASH  
353 Clinical Research Network scoring system<sup>42</sup>. MASLD was defined by the histopathological  
354 diagnosis. Detailed descriptions of study methods, comorbidity and other data definitions, case  
355 report forms, and laboratory testing are included in previous publications<sup>27,39,40</sup>. For this analysis,  
356 covariates, including participants' age, sex assigned at birth, race, and parents' income, were  
357 obtained at the time of surgery with trained study personnel<sup>27,39</sup>. Collected data were maintained  
358 in a central database by the data coordinating center.

359  
360 **Plasma-PFAS Laboratory Analysis.** The samples were transported on dry ice with temperature  
361 logging by World Courier (AmerisourceBergen Corporation, Conshohocken, PA), and stored at -  
362 80°C until analysis. The samples were analyzed by on-line solid phase extraction followed by  
363 LC-MS/MS as previously described<sup>43,44</sup>. The LOD was 0.03 ng/mL for all the reported  
364 compounds. Values below the LOD were imputed as ½ LOD. The batch imprecision for the  
365 quality controls was better than 6%.

366

367 **Plasma Metabolomics.** Untargeted plasma metabolomics were measured in plasma samples  
368 collected at the time of bariatric surgery. Liquid chromatography coupled with high-resolution  
369 mass spectrometry methods (LC-HRMS) was used as described in Liu, et al.,<sup>45</sup> with dual column  
370 and dual polarity approaches and both positive and negative electrospray ionization. This  
371 resulted in four analytical configurations: reverse phase (C18) positive, C18 negative,  
372 hydrophilic interaction (HILIC) positive, and HILIC negative. Unique features were identified  
373 using mass-to-charge ratio (m/z), retention time, and peak intensity. Features were adjusted for  
374 batch variation<sup>46</sup> and excluded if they were detected in < 20% of samples or if there was a > 30%  
375 coefficient of variability of the quality control samples after batch correction. After processing,  
376 there were 3,716 features from the C18 negative mode, 5,069 from the C18 positive mode, 7,444  
377 from the HILIC negative mode, and 6,944 from the HILIC positive mode, for a total of 23,173  
378 features included in the analyses. The raw intensity values from LC-HRMS were scaled to a  
379 standard normal distribution and log<sub>2</sub> transformed. Details of the analytical process have been  
380 described previously<sup>47</sup>. Confirmed annotations with confidence level 1 were available for 358  
381 metabolomic features<sup>48</sup>. Metabolites were identified by comparing them to authentic chemical  
382 standards under identical analytical conditions, and peaks were matched to annotations using m/z  
383 and retention time. In instances where multiple annotations were possible due to more than one  
384 molecule having retention times within the allowable error, the annotation with the closest  
385 retention time to the known standard was chosen. Measured m/z and retention times, theoretical  
386 m/z and retention times, adduct, possible annotations, and additional analytical details are listed  
387 in Excel Supplement A.

388

389 **Plasma Proteomics.** Proteins were measured in fasting plasma samples using the proximity  
390 extension array (PEA) method from Olink Explore 384 Cardiometabolic panel and Olink  
391 Explore 384 Inflammation panel<sup>49</sup>. These panels measure the relative abundance of 731 proteins,  
392 reported as normalized protein expression (NPX) levels after log<sub>2</sub> transformation<sup>50</sup>. After  
393 excluding proteins with over 50% of observations below the limit of detection (LOD) and  
394 duplicate proteins, we retained 702 proteins from the initial 731 offered after processing.

395  
396 **Liver spheroid assay.** We used the 3D InSight™ Human Liver Model (MT-02-302-04,  
397 InSphero Inc.) to test the impact of PFHpA on human liver metabolism. This model is composed  
398 of human primary hepatocytes from 10 donors (5 male and 5 female), and non-parenchymal cells  
399 from 1 donor. PFHpA (CAS#375-85-9, Sigma-Aldrich, cat# 342041) stock solution was  
400 prepared in dimethylsulfoxide (DMSO, Sigma-Aldrich). The final working solution was diluted  
401 in lean spheroid media (CS-07-305B-01, InSphero Inc.) to a final non-cytotoxic concentration of  
402 20µM of PFHpA and 0.1% DMSO<sup>51</sup>. Liver spheroids were continuously exposed to PFHpA for  
403 7 days, and culture media was replaced every 2-3 days by media containing fresh diluted  
404 PFHpA. For control, liver spheroids were exposed to 0.1% DMSO diluted in lean spheroid  
405 media cultured for 7 days following the same regimen of media replacement. Spheroids were  
406 cultured in a 96-well format, with a single spheroid per well, under sterile conditions and  
407 incubated at 37°C, 5% CO<sub>2</sub> following instructions provided by the manufacturer. We used 96  
408 spheroids per condition.

409

410 **Lipid accumulation assay and analysis.** After 7 days of treatment, spheroids were fixed with  
411 4% paraformaldehyde in phosphate-buffered saline (PBS) for 1h, permeabilized with 0.2%  
412 Triton-  
413 X100 in PBS for 30 min and blocked with 1% bovine serum albumin (BSA) in PBS for 1h at  
414 room temperature. Then, spheroids were stained with Nile Red (1 $\mu$ g/mL) and DAPI (2 $\mu$ g/mL) in  
415 1% BSA/PBS for 30 min and washed 3x with PBS. Spheroids were mounted with Prolong Gold  
416 Mounting Medium (Invitrogen) and images were acquired using a Leica TCS SP8 confocal  
417 microscope. Lipid accumulation quantification was performed using ImageJ<sup>52</sup>.

418  
419 **Single-cell RNA library preparation, sequencing, and data analysis.** Spheroids were  
420 dissociated using 0.25% trypsin for 15 min and dead cells were removed by Dead Cell Removal  
421 Kit (Miltenyi Biotech). Viable cells were partitioned with Chromium Next GEM Single Cell 3 $\times$   
422 Kit (10X Genomics). Libraries were sequenced at the USC Molecular Genomics Core using the  
423 Illumina platform. Raw data was processed using the Cell Ranger count pipeline (10X  
424 Genomics), with low-quality cell removal according to sample-specific quality control (QC)  
425 using the R package Seurat<sup>53</sup>. Comparison between PFHpA-treated and control samples was  
426 performed by integrating samples into a unified data set using the SCTransform integration  
427 workflow implemented in Seurat<sup>54</sup>. Cell annotation was based on the expression of known cell  
428 type marker genes. Differentially expressed genes between clusters from treatment groups were  
429 detected using the Wilcoxon Rank Sum test in the Seurat FindMarkers and genes with a  
430 Bonferroni adjusted p-value < 0.1 were considered significant. Biological data interpretation  
431 was performed using Ingenuity Pathways Analysis (IPA)<sup>55</sup>.

432

433 **Multi-omics data integration.** We performed knowledge-driven integration of the differentially  
434 expressed genes obtained from transcriptomic PFHpA/liver spheroids in vitro assay (GEX), and  
435 the plasma proteomics (PWAS) and metabolomics (MWAS) data obtained from the Teen-LABS  
436 cohort using the online platform OmicsNet 2.0 ([www.omicsnet.ca](http://www.omicsnet.ca))<sup>56</sup>. Briefly, OmicsNet  
437 identified the significant canonical pathways in each dataset and further separately overlapped  
438 the results from GEX and PWAS, and GEX and MWAS. We then identified the proteins and  
439 metabolites part of the overlapped pathways and used them as Omics signatures for further  
440 analysis using LUCID.

441

## 442 **Statistical Analysis**

### 443 *Plasma-PFHpA and MASLD*

444 Plasma concentrations of PFAS measured in Teen-LABS participants has been previously  
445 published<sup>23</sup>. We first evaluated the associations of 8 plasma-PFAS with MASLD (yes/no) using  
446 logistic regression and controlling for multiple comparisons via a Bonferroni correction. The  
447 plasma-PFAS concentrations were log<sub>2</sub> transformed. PFHpA was the only congener found to be  
448 associated with MASLD in our study; we therefore focused subsequent analyses on further  
449 exploring the association between plasma-PFHpA and MASLD and its features using either  
450 multinomial logistic regression models or logistic regression models, based on the number of  
451 categories in each outcome. The outcomes of interest included progression of MASLD (No  
452 MASLD, MASL not MASH, MASH; multinomial regression), hepatocellular ballooning (none,  
453 few, many; multinomial logistic regression), grade of steatosis (none, 5-33%, 34-67%;  
454 multinomial logistic regression), fibrosis (none, present; logistic regression), and MAS activity  
455 score (none, 1, 2,  $\geq 3$ ; multinomial logistic regression). For all models, we adjusted for

456 participants' age, race, sex assigned at birth, parents' annual income, and site of medical center.  
457 To test the concentration dependent-relationship between plasma-PFHpA and MASLD, we  
458 performed a generalized additive model with a low rank thin plate spline. The continuous  
459 PFHpA concentration was categorized by octiles to mitigate the influence of extremely high  
460 exposures while maintaining a readily interpretable dose-response relationship.

461

462 ***Metabolome-wide association study (MWAS)—linking PFHpA exposure with disease***  
463 ***pathways***

464 To perform the metabolome-wide analysis study, we included confirmed annotations with  
465 confidence level 1 metabolomic features<sup>48</sup>. The log-transformed metabolite intensity as included  
466 as the dependent variables and the log-transformed PFHpA concentration as the independent  
467 variable in a multiple linear regression model. We adjusted for participants' age, race, sex  
468 assigned at birth, parents' annual income, and site of medical centers to control for potential  
469 confounding. As we are not primarily interested in strict metabolite identification, we conducted  
470 an over-representation analysis for metabolites that were altered by PFHpA exposure (nominal  $p$   
471  $< 0.05$ ) using canonical pathways and diseases and biofunctions curated from Qiagen Knowledge  
472 Base using QIAGEN Ingenuity Pathway Analysis (IPA, Qiagen Inc.). For IPA results (Fig. 3),  
473 we included the pathways with the number of enriched metabolites larger than or equal to five  
474 and kept the pathway with the lowest  $p$ -value in each category. As a result, nine pathways  
475 remained and were reported in the current analysis. Then, we used a liberal threshold of nominal  
476  $p < 0.2$  to select the metabolites entering the downstream OmicsNet step in order to include all  
477 possible putative metabolites that were involved in the underlying mechanisms.

478

479 ***Proteome-wide association study (PWAS)—linking PFHpA exposure with disease pathways***

480 To perform the proteome-wide analysis study, we included the NPX levels as dependent  
481 variables and the log-transformed PFHpA concentration as the independent variable in a multiple  
482 linear regression model. We adjusted for participants' age, race, sex assigned at birth, parents'  
483 annual income, and site of medical centers to control for potential confounding. For proteins that  
484 were differentially expressed by PFHpA exposure (nominal  $p < 0.05$ ), we conducted the over-  
485 representation analysis by QIAGEN Ingenuity Pathway Analysis (IPA, Qiagen Inc.) for  
486 canonical pathways and diseases and biofunctions curated from Qiagen Knowledge Base. For  
487 IPA results (Fig. 3), we included the pathways with the number of enriched metabolites larger  
488 than or equal to five and kept the pathway with the lowest  $p$ -value in each category. In addition,  
489 as IPA yielded more pathways for PWAS than MWAS, we also used the absolute value of  $Z$ -  
490 score  $> 2$  as a cutoff. As a result, ten top pathways with the lowest  $p$ -values were reported in the  
491 current analysis. Then, we used a threshold of nominal  $p < 0.2$  to select the proteins entering the  
492 downstream OmicsNet step in order to include all possible proteins that were involved in the  
493 underlying mechanisms.

494

495 ***Multi-omics integration- Latent Unknown Clustering by Integrating multi-omics Data***  
496 ***(LUCID)***

497 Latent Unknown Clustering by Integrating multi-omics Data (LUCID) is a novel quasi-  
498 mediation analysis approach of multi-omics data that estimates the joint associations between the  
499 environmental exposure  $E$  (PFHpA), the multi-omics data  $Z$  (19 metabolites and 6 proteins that  
500 were identified through prior pre-screening procedures), and the outcome  $Y$  (MASLD) if  
501 supervised via the latent cluster variable  $X$ . The Expectation-Maximization (EM) algorithm is

502 implemented to iteratively estimate  $X$  and update the parameters until convergence. For an  
503 unsupervised LUCID model, parameters of interest include (1)  $\beta$ , representing PFHpA-to-cluster  
504 associations; (2)  $\mu$ , representing the cluster-specific means of omics features; and (3), the  
505 individual level Inclusion probability (IP) to each latent cluster. In the unsupervised LUCID  
506 approach,  $X$  integrates information from both  $E$  and  $Z$ , effectively delineating distinct risk  
507 profiles among subjects. The original LUCID framework was initially proposed for early  
508 integration of multi-omics data, entailing the concatenation of all omics layers into a single  
509 matrix. Detailed descriptions of the original LUCID have been previously introduced<sup>26</sup>. As an  
510 extension of the original LUCID, LUCID in parallel utilizes a intermediate integration strategy  
511 of the multi-omics data to estimate separate latent clusters  $X$  within each omic layer by assuming  
512 no correlations across different omics layers<sup>57</sup>. In our study, there were 2 layers of multi-omics  
513 data  $Z$ , metabolites and proteins, resulting in two individually estimated latent cluster variables,  
514  $X_{\text{metabolome}}$  and  $X_{\text{proteome}}$ . We fitted the optimal unsupervised LUCID in parallel model using  
515 PFHpA as  $E$  and pre-selected 19 metabolites and 6 proteins as  $Z$ . Based on model selection  
516 procedures using Bayesian information criterion (BIC), the number of latent clusters per omic  
517 layer of the optimal model was chosen to be 2. We extracted the IPs to  $X_{\text{metabolome}}$  and  
518  $X_{\text{proteome}}$  ( $IP_{\text{metabolome}}$  and  $IP_{\text{proteome}}$ ) from the converged optimal LUCID in parallel model.  
519  $IP_{\text{metabolome}}$  and  $IP_{\text{proteome}}$  are continuous probabilities indicating the likelihood of being  
520 included in each level of cluster  $X_{\text{metabolome}}$  and  $X_{\text{proteome}}$ , respectively. These probabilities  
521 are determined by the subjects' exposure levels, as well as the presence of metabolites and  
522 proteins, respectively. In follow up analyses to explore how  $IP_{\text{metabolome}}$  and  $IP_{\text{proteome}}$  were  
523 associated with the outcome of interest, MASLD, we fitted a logistic regression model using  
524  $IP_{\text{metabolome}}$  and  $IP_{\text{proteome}}$  as the predictors and MASLD as the binary response variable, while



525 adjust for covariates including participants' age, race, sex assigned at birth, parents' annual  
526 income, and site of medical centers.

527 **Data availability**

528 Raw and processed scRNA-seq datasets were deposited into the NCBI GEO database under the  
529 accession number GSE253186.

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545 **References**

- 546 1 Rinella, M. E. *et al.* A multisociety Delphi consensus statement on new fatty  
547 liver disease nomenclature. *Hepatology* **78**, 1966-1986 (2023).  
548 [https://doi.org:10.1097/HEP.0000000000000520](https://doi.org/10.1097/HEP.0000000000000520)
- 549 2 Chan, W. K. *et al.* Metabolic Dysfunction-Associated Steatotic Liver  
550 Disease (MASLD): A State-of-the-Art Review. *J Obes Metab Syndr* **32**,  
551 197-213 (2023). [https://doi.org:10.7570/jomes23052](https://doi.org/10.7570/jomes23052)
- 552 3 Eskridge, W. *et al.* Metabolic Dysfunction-Associated Steatotic Liver  
553 Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient  
554 and Physician Perspective. *J Clin Med* **12** (2023).  
555 [https://doi.org:10.3390/jcm12196216](https://doi.org/10.3390/jcm12196216)
- 556 4 Brecelj, J. & Orel, R. Non-Alcoholic Fatty Liver Disease in Children.  
557 *Medicina (Kaunas)* **57** (2021). [https://doi.org:10.3390/medicina57070719](https://doi.org/10.3390/medicina57070719)
- 558 5 Sweeny, K. F. & Lee, C. K. Nonalcoholic Fatty Liver Disease in Children.  
559 *Gastroenterol Hepatol (N Y)* **17**, 579-587 (2021).
- 560 6 Tidwell, J., Balassiano, N., Shaikh, A. & Nassar, M. Emerging therapeutic  
561 options for non-alcoholic fatty liver disease: A systematic review. *World J*  
562 *Hepatol* **15**, 1001-1012 (2023). [https://doi.org:10.4254/wjh.v15.i8.1001](https://doi.org/10.4254/wjh.v15.i8.1001)
- 563 7 Yugar, L. B. T. *et al.* The efficacy and safety of GLP-1 receptor agonists in  
564 youth with type 2 diabetes: a meta-analysis. *Diabetol Metab Syndr* **16**, 92  
565 (2024). [https://doi.org:10.1186/s13098-024-01337-5](https://doi.org/10.1186/s13098-024-01337-5)
- 566 8 Cusi, K. *et al.* American Association of Clinical Endocrinology Clinical  
567 Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty  
568 Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-  
569 Sponsored by the American Association for the Study of Liver Diseases  
570 (AASLD). *Endocr Pract* **28**, 528-562 (2022).  
571 [https://doi.org:10.1016/j.eprac.2022.03.010](https://doi.org/10.1016/j.eprac.2022.03.010)
- 572 9 Yanai, H., Adachi, H., Hakoshima, M., Iida, S. & Katsuyama, H. Metabolic-  
573 Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology,  
574 Association with Atherosclerosis and Cardiovascular Disease, and  
575 Treatments. *Int J Mol Sci* **24** (2023). [https://doi.org:10.3390/ijms242015473](https://doi.org/10.3390/ijms242015473)
- 576 10 Cano, R. *et al.* Role of Endocrine-Disrupting Chemicals in the Pathogenesis  
577 of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. *Int J Mol*  
578 *Sci* **22** (2021). [https://doi.org:10.3390/ijms22094807](https://doi.org/10.3390/ijms22094807)
- 579 11 Wahlang, B. *et al.* Toxicant-associated steatohepatitis. *Toxicol Pathol* **41**,  
580 343-360 (2013). [https://doi.org:10.1177/0192623312468517](https://doi.org/10.1177/0192623312468517)
- 581 12 Wahlang, B. *et al.* Mechanisms of Environmental Contributions to Fatty  
582 Liver Disease. *Curr Environ Health Rep* **6**, 80-94 (2019).  
583 [https://doi.org:10.1007/s40572-019-00232-w](https://doi.org/10.1007/s40572-019-00232-w)

- 584 13 Panieri, E., Baralic, K., Djukic-Cosic, D., Buha Djordjevic, A. & Saso, L.  
585 PFAS Molecules: A Major Concern for the Human Health and the  
586 Environment. *Toxics* **10** (2022). <https://doi.org/10.3390/toxics10020044>
- 587 14 Calafat, A. M. *et al.* Legacy and alternative per- and polyfluoroalkyl  
588 substances in the U.S. general population: Paired serum-urine data from the  
589 2013-2014 National Health and Nutrition Examination Survey. *Environ Int*  
590 **131**, 105048 (2019). <https://doi.org/10.1016/j.envint.2019.105048>
- 591 15 U.S. Centers for Disease Control and Prevention. Fourth National Report on  
592 Human Exposure to Environmental Chemicals. Updated Tables March 2018
- 593 16 Wang, Y. *et al.* A review of sources, multimedia distribution and health risks  
594 of novel fluorinated alternatives. *Ecotoxicol Environ Saf* **182**, 109402  
595 (2019). <https://doi.org/10.1016/j.ecoenv.2019.109402>
- 596 17 Sunderland, E. M. *et al.* A review of the pathways of human exposure to  
597 poly- and perfluoroalkyl substances (PFASs) and present understanding of  
598 health effects. *J Expo Sci Environ Epidemiol* **29**, 131-147 (2019).  
599 <https://doi.org/10.1038/s41370-018-0094-1>
- 600 18 Fenton, S. E. *et al.* Per- and Polyfluoroalkyl Substance Toxicity and Human  
601 Health Review: Current State of Knowledge and Strategies for Informing  
602 Future Research. *Environ Toxicol Chem* **40**, 606-630 (2021).  
603 <https://doi.org/10.1002/etc.4890>
- 604 19 Wang, P. *et al.* Adverse Effects of Perfluorooctane Sulfonate on the Liver  
605 and Relevant Mechanisms. *Toxics* **10** (2022).  
606 <https://doi.org/10.3390/toxics10050265>
- 607 20 Goodrich, J. A. *et al.* Exposure to perfluoroalkyl substances and risk of  
608 hepatocellular carcinoma in a multiethnic cohort. *JHEP Rep* **4**, 100550  
609 (2022). <https://doi.org/10.1016/j.jhepr.2022.100550>
- 610 21 Liu, Y. *et al.* Occurrence and distribution of per- and polyfluoroalkyl  
611 substances (PFASs) in human livers with liver cancer. *Environ Res* **202**,  
612 111775 (2021). <https://doi.org/10.1016/j.envres.2021.111775>
- 613 22 Costello, E. *et al.* Exposure to per- and Polyfluoroalkyl Substances and  
614 Markers of Liver Injury: A Systematic Review and Meta-Analysis. *Environ*  
615 *Health Perspect* **130**, 46001 (2022). <https://doi.org/10.1289/EHP10092>
- 616 23 Baumert, B. O. *et al.* Paired Liver:Plasma PFAS Concentration Ratios from  
617 Adolescents in the Teen-LABS Study and Derivation of Empirical and Mass  
618 Balance Models to Predict and Explain Liver PFAS Accumulation. *Environ*  
619 *Sci Technol* **57**, 14817-14826 (2023).  
620 <https://doi.org/10.1021/acs.est.3c02765>
- 621 24 Sen, P. *et al.* Exposure to environmental contaminants is associated with  
622 altered hepatic lipid metabolism in non-alcoholic fatty liver disease. *J*  
623 *Hepatol* **76**, 283-293 (2022). <https://doi.org/10.1016/j.jhep.2021.09.039>

- 624 25 Ducatman, A. & Fenton, S. E. Invited Perspective: PFAS and Liver Disease:  
625 Bringing All the Evidence Together. *Environ Health Perspect* **130**, 41303  
626 (2022). <https://doi.org:10.1289/EHP11149>
- 627 26 Peng, C. *et al.* A latent unknown clustering integrating multi-omics data  
628 (LUCID) with phenotypic traits. *Bioinformatics* **36**, 842-850 (2020).  
629 <https://doi.org:10.1093/bioinformatics/btz667>
- 630 27 Inge, T. H. *et al.* Teen-Longitudinal Assessment of Bariatric Surgery:  
631 methodological features of the first prospective multicenter study of  
632 adolescent bariatric surgery. *J Pediatr Surg* **42**, 1969-1971 (2007).  
633 <https://doi.org:10.1016/j.jpedsurg.2007.08.010>
- 634 28 Xu, Y. *et al.* Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl  
635 Acids after Ceasing Exposure from Drinking Water Contaminated by  
636 Firefighting Foam. *Environ Health Perspect* **128**, 77004 (2020).  
637 <https://doi.org:10.1289/EHP6785>
- 638 29 Yang, Y. *et al.* In-situ fabrication of a spherical-shaped Zn-Al hydrotalcite  
639 with BiOCl and study on its enhanced photocatalytic mechanism for  
640 perfluorooctanoic acid removal performed with a response surface  
641 methodology. *J Hazard Mater* **399**, 123070 (2020).  
642 <https://doi.org:10.1016/j.jhazmat.2020.123070>
- 643 30 Yuan, Y., Feng, L., Xie, N., Zhang, L. & Gong, J. Rapid photochemical  
644 decomposition of perfluorooctanoic acid mediated by a comprehensive  
645 effect of nitrogen dioxide radicals and Fe(3+)/Fe(2+) redox cycle. *J Hazard*  
646 *Mater* **388**, 121730 (2020). <https://doi.org:10.1016/j.jhazmat.2019.121730>
- 647 31 Gong, C., Sun, X., Zhang, C., Zhang, X. & Niu, J. Kinetics and quantitative  
648 structure-activity relationship study on the degradation reaction from  
649 perfluorooctanoic acid to trifluoroacetic acid. *Int J Mol Sci* **15**, 14153-14165  
650 (2014). <https://doi.org:10.3390/ijms150814153>
- 651 32 David, N. *et al.* Associations between perfluoroalkyl substances and the  
652 severity of non-alcoholic fatty liver disease. *Environ Int* **180**, 108235 (2023).  
653 <https://doi.org:10.1016/j.envint.2023.108235>
- 654 33 Tyagi, S., Gupta, P., Saini, A. S., Kaushal, C. & Sharma, S. The peroxisome  
655 proliferator-activated receptor: A family of nuclear receptors role in various  
656 diseases. *J Adv Pharm Technol Res* **2**, 236-240 (2011).  
657 <https://doi.org:10.4103/2231-4040.90879>
- 658 34 Reddy, J. K. & Hashimoto, T. Peroxisomal beta-oxidation and peroxisome  
659 proliferator-activated receptor alpha: an adaptive metabolic system. *Annu*  
660 *Rev Nutr* **21**, 193-230 (2001). <https://doi.org:10.1146/annurev.nutr.21.1.193>
- 661 35 Wolf, C. J., Takacs, M. L., Schmid, J. E., Lau, C. & Abbott, B. D.  
662 Activation of mouse and human peroxisome proliferator-activated receptor  
663 alpha by perfluoroalkyl acids of different functional groups and chain

- 664 lengths. *Toxicol Sci* **106**, 162-171 (2008).  
665 <https://doi.org/10.1093/toxsci/kfn166>
- 666 36 Rosen, M. B. *et al.* PPARalpha-independent transcriptional targets of  
667 perfluoroalkyl acids revealed by transcript profiling. *Toxicology* **387**, 95-107  
668 (2017). <https://doi.org/10.1016/j.tox.2017.05.013>
- 669 37 Wolf, C. J., Schmid, J. E., Lau, C. & Abbott, B. D. Activation of mouse and  
670 human peroxisome proliferator-activated receptor-alpha (PPARalpha) by  
671 perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds.  
672 *Reprod Toxicol* **33**, 546-551 (2012).  
673 <https://doi.org/10.1016/j.reprotox.2011.09.009>
- 674 38 Yang, W. *et al.* PPARalpha/ACOX1 as a novel target for hepatic lipid  
675 metabolism disorders induced by per- and polyfluoroalkyl substances: An  
676 integrated approach. *Environ Int* **178**, 108138 (2023).  
677 <https://doi.org/10.1016/j.envint.2023.108138>
- 678 39 Inge, T. H. *et al.* Perioperative outcomes of adolescents undergoing bariatric  
679 surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-  
680 LABS) study. *JAMA Pediatr* **168**, 47-53 (2014).  
681 <https://doi.org/10.1001/jamapediatrics.2013.4296>
- 682 40 Inge, T. H. *et al.* Weight Loss and Health Status 3 Years after Bariatric  
683 Surgery in Adolescents. *N Engl J Med* **374**, 113-123 (2016).  
684 <https://doi.org/10.1056/NEJMoa1506699>
- 685 41 Xanthakos, S. A. *et al.* High Prevalence of Nonalcoholic Fatty Liver Disease  
686 in Adolescents Undergoing Bariatric Surgery. *Gastroenterology* **149**, 623-  
687 634 e628 (2015). <https://doi.org/10.1053/j.gastro.2015.05.039>
- 688 42 Kleiner, D. E. *et al.* Design and validation of a histological scoring system  
689 for nonalcoholic fatty liver disease. *Hepatology* **41**, 1313-1321 (2005).  
690 <https://doi.org/10.1002/hep.20701>
- 691 43 Haug, L. S., Thomsen, C. & Becher, G. A sensitive method for  
692 determination of a broad range of perfluorinated compounds in serum  
693 suitable for large-scale human biomonitoring. *J Chromatogr A* **1216**, 385-  
694 393 (2009). <https://doi.org/10.1016/j.chroma.2008.10.113>
- 695 44 Eryasa, B. *et al.* Physico-chemical properties and gestational diabetes predict  
696 transplacental transfer and partitioning of perfluoroalkyl substances. *Environ*  
697 *Int* **130**, 104874 (2019). <https://doi.org/10.1016/j.envint.2019.05.068>
- 698 45 Liu, K. H. *et al.* Reference Standardization for Quantification and  
699 Harmonization of Large-Scale Metabolomics. *Anal Chem* **92**, 8836-8844  
700 (2020). <https://doi.org/10.1021/acs.analchem.0c00338>
- 701 46 Luan, H., Ji, F., Chen, Y. & Cai, Z. statTarget: A streamlined tool for signal  
702 drift correction and interpretations of quantitative mass spectrometry-based

- 703 omics data. *Anal Chim Acta* **1036**, 66-72 (2018).  
704 <https://doi.org/10.1016/j.aca.2018.08.002>
- 705 47 Goodrich, J. A. *et al.* Metabolic Signatures of Youth Exposure to Mixtures  
706 of Per- and Polyfluoroalkyl Substances: A Multi-Cohort Study. *Environ*  
707 *Health Perspect* **131**, 27005 (2023). <https://doi.org/10.1289/EHP11372>
- 708 48 Schymanski, E. L. *et al.* Identifying small molecules via high resolution  
709 mass spectrometry: communicating confidence. *Environ Sci Technol* **48**,  
710 2097-2098 (2014). <https://doi.org/10.1021/es5002105>
- 711 49 Assarsson, E. *et al.* Homogenous 96-plex PEA immunoassay exhibiting high  
712 sensitivity, specificity, and excellent scalability. *PLoS One* **9**, e95192  
713 (2014). <https://doi.org/10.1371/journal.pone.0095192>
- 714 50 Petrera, A. *et al.* Multiplatform Approach for Plasma Proteomics:  
715 Complementarity of Olink Proximity Extension Assay Technology to Mass  
716 Spectrometry-Based Protein Profiling. *J Proteome Res* **20**, 751-762 (2021).  
717 <https://doi.org/10.1021/acs.jproteome.0c00641>
- 718 51 Rowan-Carroll, A. *et al.* High-Throughput Transcriptomic Analysis of  
719 Human Primary Hepatocyte Spheroids Exposed to Per- and Polyfluoroalkyl  
720 Substances as a Platform for Relative Potency Characterization. *Toxicol Sci*  
721 **181**, 199-214 (2021). <https://doi.org/10.1093/toxsci/kfab039>
- 722 52 Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ:  
723 25 years of image analysis. *Nat Methods* **9**, 671-675 (2012).  
724 <https://doi.org/10.1038/nmeth.2089>
- 725 53 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating  
726 single-cell transcriptomic data across different conditions, technologies, and  
727 species. *Nat Biotechnol* **36**, 411-420 (2018).  
728 <https://doi.org/10.1038/nbt.4096>
- 729 54 Hafemeister, C. & Satija, R. Normalization and variance stabilization of  
730 single-cell RNA-seq data using regularized negative binomial regression.  
731 *Genome Biol* **20**, 296 (2019). <https://doi.org/10.1186/s13059-019-1874-1>
- 732 55 Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis  
733 approaches in Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523-530  
734 (2014). <https://doi.org/10.1093/bioinformatics/btt703>
- 735 56 Zhou, G., Pang, Z., Lu, Y., Ewald, J. & Xia, J. OmicsNet 2.0: a web-based  
736 platform for multi-omics integration and network visual analytics. *Nucleic*  
737 *Acids Res* **50**, W527-W533 (2022). <https://doi.org/10.1093/nar/gkac376>
- 738 57 Jia, Q., Zhao, Y., Conti, D., & Goodrich, J. . Package ‘LUCIDus’. *R*  
739 *Foundation*. (2023).  
740

## Tables and Figures

**Table 1.** Characteristics of Teen-LABS cohort (N=136)


Age (years), mean (SD)	17.1 (1.5)
White, n (%)	93 (68.4%)
Female, n (%)	100 (73.5%)
Parent's income, less than \$75,000, mean (SD)	111 (81.6%)
BMI (kg/m <sup>2</sup> ), mean (SD)	53.8 (9.8)

BMI: Body Mass Index

**Table 2.** Refined outcomes of SLD in Teen-LABS (N=136)

	n (%)
MASLD	
No MASLD	55 (40.4)
MASLD	81 (59.6%)
MASLD severity	
No MASLD	55 (40.4)
MASLD, not MASH	51 (37.5)
MASH	30 (22.1)
MAFLD Activity Score (MAS)	
none	25 (18.4)
1	41 (30.1)
2	37 (27.2)
≥3	33 (24.3)
Fibrosis	
None	110 (80.9)
Present	26 (19.1)
Steatosis	
None	106 (77.9)
5 - 33%	18 (13.2)
34 - >67%	12 (8.9)
Hepatocellular ballooning	
None	115 (84.6)
Few	16 (11.8)
Many	5 (3.6)

Metabolic dysfunction-associated steatotic liver disease (MASLD); Steatotic liver disease (SLD); The MAS can range from 0 to 8 and is calculated by the sum of scores of steatosis (0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-2).




**Figure 1.** Translational framework.

(a) Teen-LABS study design

(b) Human liver spheroids composed of primary hepatocytes and non-parenchymal cells (NPCs) were exposed to 20µM PFHpA for 7 days. Culture media was changed every 2-3 days to ensure constant PFHpA presence in culture media. At the end of the culture period, spheroids were dissociated into single cells, and viable cells were partitioned using the 10x Genomics platform. Single-cell gene expression libraries were sequenced using the Illumina platform. Created with [BioRender.com](https://www.biorender.com).

(c) Data integration workflow. We used the OmicsNet 2.0 platform to integrate 156 differentially expressed genes upregulated in PFHpA-exposed spheroids (GEX), 42 metabolites (MWAS), and 28 proteins (PWAS) upregulated in the plasma of MAFLD subjects (compared to non-MAFLD controls). After analyzing the overlapped pathways between GEX-MWAS and GEX-PWAS, we identified 19 metabolites and 6 proteins that will be used for further analysis. Created with [BioRender.com](https://www.biorender.com)






**Figure 2.** PFHpA exposure, histopathological determined outcomes of MASLD in the Teen-LABS study

(a) Shows the odds ratio (OR) and 95% confidence intervals (95% CIs) for the association between PFHpA (ng/mL) and histopathological determined MASLD (N=136). Multinomial logistic regression between PFHpA and severity of MASLD (No MASLD, MASL not MASH, MASH). The models controls for: age, sex, race, parental income, study site. Results are shown as log<sub>2</sub> of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(b) The association between octiles of PFHpA and histopathological determined MASLD (N=136). Model adjusted for: age, sex, race, parental income, study site. Results are shown as log<sub>2</sub> of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(c) The association between PFHpA and histopathological determined outcomes of SLD (N=136). Figure 1c shows the odds ratio (OR) and 95% confidence intervals (95% CIs) for the association between PFHpA (ng/mL) measured in plasma and refined outcomes of SLD. Multinomial logistic regression between PFHpA and hepatocellular ballooning, steatosis grade, and MASLD Activity Score (MAS); Logistic regression between PFHpA and presence (y/n) of fibrosis. All models adjusted for: age, sex, race, parental income, study site. Results are shown as log<sub>2</sub> of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.




**Figure 3.** Omics-Wide Association Study in Teen-LABS

(a) Volcano plot showing the MWAS for PFHpA and metabolites from adolescents in Teen-LABS. Linear regression between PFHpA and metabolites (N=131) adjusting for age, sex, race, parental income, study site.

(b) Volcano plot showing the PWAS for PFHpA and proteins (N=131) from adolescents in Teen-LABS. Linear regression between PFHpA and proteins (N=131) adjusting for age, sex, race, parental income, study site.


(c) Enriched pathways from the MWAS for PFHpA and metabolites from adolescents in Teen-LABS. Linear regression between PFHpA and metabolites (N=131) adjusting for age, sex, race, parental income, study site.

(d) Enriched pathways from the PWAS for PFHpA and proteins (N=131) from adolescents in Teen-LABS. Linear regression between PFHpA and proteins (N=131) adjusting for age, sex, race, parental income, study site.



**Figure 4.** PFHpA exposure disturbs lipid metabolism in human liver spheroids.


- (a) Integrated UMAP of control and PFHpA-exposed spheroids. We observed the presence of hepatocytes, Kupffer cells, T cells, NK cells, endothelial cells, and B cells.
- (b) Differentially expressed (DE) genes detected in whole liver spheroid (global) and individual cell clusters.
- (c) Canonical pathways upregulated by PFHpA in whole liver spheroids. Around 48% of the pathways upregulated by PFHpA were related to lipid metabolism, while 20% were related to amino acid metabolism. Other important pathways were related to detoxification (13.8%), energy metabolism (6.9%), protein trafficking, hormone metabolism, and cell growth and differentiation.
- (d) Canonical pathways upregulated by PFHpA in T cells. Most of the pathways upregulated in T cells were related to lipid metabolism (40%) and amino acid metabolism (20%). Other pathways were related to cell death, detoxification, protein trafficking, and stress response.
- (e) Canonical pathways upregulated by PFHpA in hepatocytes. Almost 45% of the pathways upregulated in hepatocytes were related to lipid metabolism, and around 18% of the pathways were related to amino acid metabolism. Other important categories upregulated were energy metabolism, protein trafficking, and carbohydrate metabolism.
- (f) Upregulated pathways related to lipid metabolism in hepatocytes from spheroids exposed to PFHpA.
- (g) Lipid accumulation in liver spheroids. Confocal imaging of spheroids stained with Nile Red suggests an increase in lipid accumulation (red) in cells from liver spheroids exposed to PFHpA.
- (h) Digital quantification of confocal imaging using ImageJ confirms a significant increase in lipid accumulation due to PFHpA exposure. CTCF = Correlated Total Cell Fluorescence



**Figure 5.** Integration of in vitro and in vivo datasets for identification of proteomic and metabolomic signatures.

(a) Pathways commonly found in GEX (in vitro) and MWAS (in vivo) datasets. The shown pathways are composed of genes and metabolites. The majority of the pathways are related to lipid metabolism and amino acid metabolism.

(b) Pathways commonly found in GEX (in vitro) and PWAS (in vivo) datasets. The shown pathways are composed of genes and proteins. The most significant pathway is related to lipid metabolism (fatty acid degradation [ $-\log_{10}(\text{FDR})= 12.97$ ]).



**Figure 6.** Multi-omics integration of PFHpA, proteomics, and metabolomics to determine clusters of individuals at high risk for MASLD (N=131).

We identified two distinct multi-omic risk profiles associated with high PFHpA exposure and higher odds of MASLD. The first omic risk profile showed an association between high PFHpA levels and increased proteins. MASLD was 7 times more likely in this PFHpA-protein risk profile. The second omic risk profile showed an association between high PFHpA and altered levels of amino acids and lipids metabolites.

(a) Shows the association of PIPS from unsupervised LUCID and MAFLD (No, Yes), N= 131. The model includes the two layers in the same model. REF = NO MASLD, model adjusted for study site, age, sex, race, parental income. The reference cluster for the proteins is the high-risk cluster and for the metabolites the reference cluster is the low-risk cluster. Results are shown as log<sub>2</sub> of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.

(b) Demonstrates the high and low risk for MASLD groups of individuals by the clusters of metabolites and proteins. Results are shown as log<sub>2</sub> of PFHpA exposure and therefore interpreted as per doubling of PFHpA exposure.